ReviewJournal of pharmaceutical policy and practice2020

Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab and imatinib.

Yuanqiong Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.